@article{MTMT:34107493,
	title = {Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2},
	url = {https://m2.mtmt.hu/api/publication/34107493},
	author = {Pietiäinen, Vilja and Polso, Minttu and Migh, Ede and Guckelsberger, Christian and Harmati, Mária and Diósdi, Ákos and Turunen, Laura and Hassinen, Antti and Potdar, Swapnil and Koponen, Annika and Gyukity-Sebestyén, Edina and Kovács, Ferenc and Kriston, András and Hollandi, Réka and Burián, Katalin and Terhes, Gabriella and Visnyovszki, Ádám and Fodor, Eszter and Lacza, Zsombor and Kantele, Anu and Kolehmainen, Pekka and Kakkola, Laura and Strandin, Tomas and Levanov, Lev and Kallioniemi, Olli and Kemény, Lajos and Julkunen, Ilkka and Vapalahti, Olli and Buzás, Krisztina and Paavolainen, Lassi and Horváth, Péter and Hepojoki, Jussi},
	doi = {10.1016/j.crmeth.2023.100565},
	journal-iso = {CELL REP METH},
	journal = {CELL REPORTS METHODS},
	volume = {3},
	unique-id = {34107493},
	issn = {2667-2375},
	abstract = {We present a miniaturized immunofluorescence assay (mini-IFA) for measuring antibody response in patient blood samples. The method utilizes machine learning-guided image analysis and enables simultaneous mea- surement of immunoglobulin M (IgM), IgA, and IgG responses against different viral antigens in an automated and high-throughput manner. The assay relies on antigens expressed through transfection, enabling use at a low biosafety level and fast adaptation to emerging pathogens. Using severe acute respiratory syndrome co- ronavirus 2 (SARS-CoV-2) as the model pathogen, we demonstrate that this method allows differentiation be- tween vaccine-induced and infection-induced antibody responses. Additionally, we established a dedicated web page for quantitative visualization of sample-specific results and their distribution, comparing them with controls and other samples. Our results provide a proof of concept for the approach, demonstrating fast and accurate measurement of antibody responses in a research setup with prospects for clinical diagnostics.},
	year = {2023},
	eissn = {2667-2375},
	orcid-numbers = {Harmati, Mária/0000-0002-4875-5723; Gyukity-Sebestyén, Edina/0000-0003-1383-6301; Burián, Katalin/0000-0003-1300-2374; Terhes, Gabriella/0000-0002-7301-9672; Kemény, Lajos/0000-0002-2119-9501; Buzás, Krisztina/0000-0001-8933-2033}
}

@article{MTMT:32039122,
	title = {COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses},
	url = {https://m2.mtmt.hu/api/publication/32039122},
	author = {Sahin, Ugur and Muik, Alexander and Derhovanessian, Evelyna and Vogler, Isabel and Kranz, Lena M. and Vormehr, Mathias and Baum, Alina and Pascal, Kristen and Quandt, Jasmin and Maurus, Daniel and Brachtendorf, Sebastian and Loerks, Verena and Sikorski, Julian and Hilker, Rolf and Becker, Dirk and Eller, Ann-Kathrin and Gruetzner, Jan and Boesler, Carsten and Rosenbaum, Corinna and Kuehnle, Marie-Cristine and Luxemburger, Ulrich and Kemmer-Brueck, Alexandra and Langer, David and Bexon, Martin and Bolte, Stefanie and Karikó, Katalin and Palanche, Tania and Fischer, Boris and Schultz, Armin and Shi, Pei-Yong and Fontes-Garfias, Camila and Perez, John L. and Swanson, Kena A. and Loschko, Jakob and Scully, Ingrid L. and Cutler, Mark and Kalina, Warren and Kyratsous, Christos A. and Cooper, David and Dormitzer, Philip R. and Jansen, Kathrin U. and Tuereci, Oezlem},
	doi = {10.1038/s41586-020-2814-7},
	journal-iso = {NATURE},
	journal = {NATURE},
	volume = {586},
	unique-id = {32039122},
	issn = {0028-0836},
	abstract = {In a phase I/II dose-escalation clinical trial, the mRNA COVID-19 vaccine BNT162b1 elicits specific T cell and antibody responses that suggest it has protective potential. An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein(1). Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18-55 years of age. Two doses of 1-50 mu g of BNT162b1 elicited robust CD4(+)and CD8(+)T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-mu g dose) to 3.5-fold (50-mu g dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (T(H)1)-skewed T cell immune responses with RBD-specific CD8(+)and CD4(+)T cell expansion. Interferon-gamma was produced by a large fraction of RBD-specific CD8(+)and CD4(+)T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.},
	keywords = {RNA; CAPACITY; CORONAVIRUS},
	year = {2020},
	eissn = {1476-4687},
	pages = {594-599},
	orcid-numbers = {Muik, Alexander/0000-0003-4561-2273; Kranz, Lena M./0000-0003-1943-3431; Vormehr, Mathias/0000-0001-7788-3380; Hilker, Rolf/0000-0002-8576-7731; Karikó, Katalin/0000-0002-1864-3851; Fontes-Garfias, Camila/0000-0002-1912-8413}
}